Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis

Reviews in Cardiovascular Medicine

Volumn 4, Issue 3, 2003, Pages 136-141

  Shah, Prediman K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Avasimibe; Cholesterol; Ezetimibe; Guggulsterone; HMG CoA reductase inhibitors

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; ATORVASTATIN; AVASIMIBE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; EZETIMIBE; GUGGULSTERONE; GW 532; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; ENZYME INHIBITION; HUMAN; LIPID ABSORPTION; MONOTHERAPY; MORTALITY; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; HUMANS; HYPERLIPIDEMIAS;

EID: 0041827050     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
3. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation. 2001;104:2498-2502.
4. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001;104:2376-2383.
5. Mensink RP, Ebbing S, Lindhout M, Plat J, van Heugten MM. Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations. Atherosclerosis. 2002;160:205-213.
6. Plat J, Mensink RP. Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption. Faseb J. 2002;16:1248-1253.
7. Sudhop T, Von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 2002;62:2333-2347.
8. Stein EA. An investigative look: selective cholesterol absorption inhibitors- embarking on a new standard of care. Am J Manag Care. 2002;8:S36-S39; discussion S45-7.
9. Leitersdorf E. Selective cholesterol absorption inhibition: a novel strategy in lipid- lowering management. Int J Clin Pract. 2002;56:116-119.
10. Turley SD. State of the art in cholesterol management: targeting multiple pathways. Am J Manag Care. 2002;8:S29-S32; discussion S45-S47.
11. Heinzl S. [Ezetimib. A new cholesterol absorption inhibitor]. Med Monatsschr Pharm. 2002;25:229-232.
12. Meng CQ. Ezetimibe. Schering-Plough. Curr Opin Investig Drugs. 2002;3:427-432.
13. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-2475.
14. Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos. 2002;30:430-437.
15. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002;54:309-319.
16. Buhman KF, Accad M, Farese RV. Mammalian acyl-CoA:cholesterol acyltransferases. Biochim Biophys Acta. 2000;1529:142-154.
17. Accad M, Smith SJ, Newland DL et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J Clin Invest. 2000;105:711-719.
18. Fazio S, Major AS, Swift LL, et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest. 2001;107:163-171.
19. Rudel LL, Shelness GS. Cholesterol esters and atherosclerosis-a game of ACAT and mouse. Nat Med. 2000;6:1313-1314.
20. Kusunoki J, Hansoty DK, Aragane K, et al. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:2604-2609.
21. Chiwata T, Aragane K, Fujinami K, et al. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F- 1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Br J Pharmacol. 2001;133:1005-1012.
22. Buhman KK, Accad M, Novak S, et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med. 2000;6:1341-1347.
23. Heinonen TM. Inhibition of acyl coenzyme A-cholesterol acyltransferase: A possible treatment of atherosclerosis? Curr Atheroscler Rep. 2002;4:65-70.
24. Tardif JC, Gregoire J, Lesperance J, et al. Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial. Am Heart J. 2002;144:589-596.
25. Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 1994;8:659-664.
26. Ghorai M, Mandal SC, Pal M, et al. A comparative study on hypocholesterolaemic effect of allicin, whole germinated seeds of bengal gram and guggulipid of gum gugglu. Phytother Res. 2000;14:200-202.
27. Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002;296:1703-1706.
28. Grand-Perret T, Bouillot A, Perrot A, et al. SCAP ligands are potent new lipid-lowering drugs. Nat Med. 2001;7:1332-1338.
29. Rader DJ. A new feature on the cholesterol-lowering landscape. Nat Med. 2001;7:1282-1284.
30. Jamil H, Chu CH, Dickson JK, Jr., et al. Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J Lipid Res. 1998;39:1448-1454.
31. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 1998;282:751-754.
32. Datta G, Garber DW, Chung BH, et al. Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res. 2001;42:959-966.